Plant-based Vaccines for Alzheimer's Disease

Overview

Journal Proc Jpn Acad Ser B Phys Biol Sci

Specialties Biology
Science

Date 2019 Jun 14

PMID 31189781

Citations 3

Authors

Shoichi Ishiura

Taiji Yoshida

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is one of the major causes of chronic and progressive cognitive decline, with the pathological hallmarks of senile plaques and neurofibrillary tangles. Amyloid β peptide (Aβ) is the main component of senile plaques, and the pathological load of Aβ in the brain has been shown to be a marker of the severity of AD. To prevent the accumulation of plaques, novel and safer plant-based vaccine strategies have been suggested. In this review, we summarize the results of plant vaccines against Aβ.

Citing Articles

Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines.

Vo D, Trinh K Vaccines (Basel). 2025; 13(2).

PMID: 40006737 PMC: 11860421. DOI: 10.3390/vaccines13020191.

Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases.

Bravo-Vazquez L, Mora-Hernandez E, Rodriguez A, Sahare P, Bandyopadhyay A, Duttaroy A Pharmaceutics. 2023; 15(2).

PMID: 36840033 PMC: 9963606. DOI: 10.3390/pharmaceutics15020711.

Immunotherapies for Alzheimer's Disease-A Review.

Valiukas Z, Ephraim R, Tangalakis K, Davidson M, Apostolopoulos V, Feehan J Vaccines (Basel). 2022; 10(9).

PMID: 36146605 PMC: 9503401. DOI: 10.3390/vaccines10091527.

Hepatitis C virus E2 envelope glycoprotein produced in Nicotiana benthamiana triggers humoral response with virus-neutralizing activity in vaccinated mice.

Dobrica M, van Eerde A, tucureanu C, Onu A, Paruch L, Caras I Plant Biotechnol J. 2021; 19(10):2027-2039.

PMID: 34002936 PMC: 8486241. DOI: 10.1111/pbi.13631.

References

Potrykus I . Lessons from the 'Humanitarian Golden Rice' project: regulation prevents development of public good genetically engineered crop products. N Biotechnol. 2010; 27(5):466-72. DOI: 10.1016/j.nbt.2010.07.012. View

Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618):50-6. DOI: 10.1038/nature19323. View

Yoshida T, Kimura E, Koike S, Nojima J, Futai E, Sasagawa N . Transgenic rice expressing amyloid β-peptide for oral immunization. Int J Biol Sci. 2011; 7(3):301-7. PMC: 3065743. DOI: 10.7150/ijbs.7.301. View

Vina J, Sanz-Ros J . Alzheimer's disease: Only prevention makes sense. Eur J Clin Invest. 2018; 48(10):e13005. DOI: 10.1111/eci.13005. View

Imtiaz B, Tolppanen A, Kivipelto M, Soininen H . Future directions in Alzheimer's disease from risk factors to prevention. Biochem Pharmacol. 2014; 88(4):661-70. DOI: 10.1016/j.bcp.2014.01.003. View

Doody R, Thomas R, Farlow M, Iwatsubo T, Vellas B, Joffe S . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):311-21. DOI: 10.1056/NEJMoa1312889. View

Rosales-Mendoza S, Rubio-Infante N, Zarazua S, Govea-Alonso D, Martel-Gallegos G, Moreno-Fierros L . Plant-based vaccines for Alzheimer's disease: an overview. Expert Rev Vaccines. 2014; 13(3):429-41. DOI: 10.1586/14760584.2014.874948. View

Szabo B, Hori K, Nakajima A, Sasagawa N, Watanabe Y, Ishiura S . Expression of amyloid-beta 1-40 and 1-42 peptides in Capsicum annum var. angulosum for oral immunization. Assay Drug Dev Technol. 2004; 2(4):383-8. DOI: 10.1089/adt.2004.2.383. View

Sterner R, Takahashi P, Yu Ballard A . Active Vaccines for Alzheimer Disease Treatment. J Am Med Dir Assoc. 2016; 17(9):862.e11-5. DOI: 10.1016/j.jamda.2016.06.009. View

10.

Bayer A, Bullock R, Jones R, Wilkinson D, Paterson K, Jenkins L . Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005; 64(1):94-101. DOI: 10.1212/01.WNL.0000148604.77591.67. View

11.

Nojima J, Maeda A, Aoki S, Suo S, Yanagihara D, Watanabe Y . Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model. Vaccine. 2011; 29(37):6252-8. DOI: 10.1016/j.vaccine.2011.06.073. View

12.

Selkoe D, Schenk D . Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2002; 43:545-84. DOI: 10.1146/annurev.pharmtox.43.100901.140248. View

13.

Doody R, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S . A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013; 369(4):341-50. DOI: 10.1056/NEJMoa1210951. View

14.

Egan M, Kost J, Tariot P, Aisen P, Cummings J, Vellas B . Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2018; 378(18):1691-1703. PMC: 6776074. DOI: 10.1056/NEJMoa1706441. View

15.

Youm J, Kim H, Han J, Jang C, Ha H, Mook-Jung I . Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model. FEBS Lett. 2005; 579(30):6737-44. DOI: 10.1016/j.febslet.2005.11.003. View

16.

Orgogozo J, Gilman S, Dartigues J, Laurent B, Puel M, Kirby L . Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003; 61(1):46-54. DOI: 10.1212/01.wnl.0000073623.84147.a8. View

17.

Hock C, Konietzko U, Streffer J, Tracy J, Signorell A, Muller-Tillmanns B . Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003; 38(4):547-54. DOI: 10.1016/s0896-6273(03)00294-0. View

18.

Querfurth H, LaFerla F . Alzheimer's disease. N Engl J Med. 2010; 362(4):329-44. DOI: 10.1056/NEJMra0909142. View

19.

Cummings J, Tong G, Ballard C . Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. J Alzheimers Dis. 2019; 67(3):779-794. PMC: 6398562. DOI: 10.3233/JAD-180766. View

20.

Ishii-Katsuno R, Nakajima A, Katsuno T, Nojima J, Futai E, Sasagawa N . Reduction of amyloid beta-peptide accumulation in Tg2576 transgenic mice by oral vaccination. Biochem Biophys Res Commun. 2010; 399(4):593-9. DOI: 10.1016/j.bbrc.2010.07.120. View